Sequenom secures IP for noninvasive genetic prenatal tests
This article was originally published in Clinica
Sequenom has acquired exclusive rights in the US and certain European countries, including the UK, to intellectual property (IP) relating to noninvasive prenatal diagnostics held by Isis Innovation, the technology transfer company of the University of Oxford in the UK.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.